Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B1962 in Advanced Malignant Solid Tumors
NCT06724263Phase 2Not yet recruiting
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Aug 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of B1962 in epithelial ovarian cancer (EOC), triple-negative breast cancer (TNBC), Cervical Cancer (CC), small cell lung cancer (SCLC), biliary tract cancer (BTC), sponsored by Tasly Biopharmaceuticals Co., Ltd.. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
B1962
03
Conditions
epithelial ovarian cancer (EOC)triple-negative breast cancer (TNBC)Cervical Cancer (CC)small cell lung cancer (SCLC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06724263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06724263.